CGC Quote, Financials, Valuation and Earnings

Edesa Biotech has a net margin of -163.05% compared to Canopy Growth's net margin of --. Canopy Growth's return on equity of -87.32% beat Edesa Biotech's return on equity of --.

Canopy Growth has a consensus price target of $2.23, signalling upside risk potential of 70.6%. On the other hand Edesa Biotech has an analysts' consensus of $19.00 which suggests that it could grow by 829.1%. Given that Edesa Biotech has higher upside potential than Canopy Growth, analysts believe Edesa Biotech is more attractive than Canopy Growth.

Canopy Growth has a beta of 0.790, which suggesting that the stock is 21.029% less volatile than S&P 500. In comparison Edesa Biotech has a beta of 0.547, suggesting its less volatile than the S&P 500 by 45.291%.

Canopy Growth has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edesa Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Canopy Growth pays -- of its earnings as a dividend. Edesa Biotech pays out -- of its earnings as a dividend.

Canopy Growth quarterly revenues are $53.3M, which are larger than Edesa Biotech quarterly revenues of --. Canopy Growth's net income of -$86.8M is lower than Edesa Biotech's net income of -$1.6M. Notably, Canopy Growth's price-to-earnings ratio is -- while Edesa Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Canopy Growth is 0.59x versus 20.23x for Edesa Biotech. Usually stocks with elevated PS ratios are considered overvalued.

Lexaria Bioscience has a net margin of -163.05% compared to Canopy Growth's net margin of -1559.32%. Canopy Growth's return on equity of -87.32% beat Lexaria Bioscience's return on equity of -118.15%.

Canopy Growth has a consensus price target of $2.23, signalling upside risk potential of 70.6%. On the other hand Lexaria Bioscience has an analysts' consensus of $7.00 which suggests that it could grow by 548.15%. Given that Lexaria Bioscience has higher upside potential than Canopy Growth, analysts believe Lexaria Bioscience is more attractive than Canopy Growth.

Canopy Growth has a beta of 0.790, which suggesting that the stock is 21.029% less volatile than S&P 500. In comparison Lexaria Bioscience has a beta of 1.008, suggesting its more volatile than the S&P 500 by 0.806%.

Canopy Growth has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexaria Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Canopy Growth pays -- of its earnings as a dividend. Lexaria Bioscience pays out -- of its earnings as a dividend.

Canopy Growth quarterly revenues are $53.3M, which are larger than Lexaria Bioscience quarterly revenues of $174K. Canopy Growth's net income of -$86.8M is lower than Lexaria Bioscience's net income of -$2.7M. Notably, Canopy Growth's price-to-earnings ratio is -- while Lexaria Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Canopy Growth is 0.59x versus 32.73x for Lexaria Bioscience. Usually stocks with elevated PS ratios are considered overvalued.

Viatris has a net margin of -163.05% compared to Canopy Growth's net margin of -93.48%. Canopy Growth's return on equity of -87.32% beat Viatris's return on equity of -20.24%.

Canopy Growth has a consensus price target of $2.23, signalling upside risk potential of 70.6%. On the other hand Viatris has an analysts' consensus of $11.7471 which suggests that it could grow by 33.95%. Given that Canopy Growth has higher upside potential than Viatris, analysts believe Canopy Growth is more attractive than Viatris.

Canopy Growth has a beta of 0.790, which suggesting that the stock is 21.029% less volatile than S&P 500. In comparison Viatris has a beta of 0.887, suggesting its less volatile than the S&P 500 by 11.265%.

Canopy Growth has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viatris offers a yield of 5.47% to investors and pays a quarterly dividend of $0.12 per share. Canopy Growth pays -- of its earnings as a dividend. Viatris pays out -90.63% of its earnings as a dividend.

Canopy Growth quarterly revenues are $53.3M, which are smaller than Viatris quarterly revenues of $3.3B. Canopy Growth's net income of -$86.8M is higher than Viatris's net income of -$3B. Notably, Canopy Growth's price-to-earnings ratio is -- while Viatris's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Canopy Growth is 0.59x versus 0.73x for Viatris. Usually stocks with elevated PS ratios are considered overvalued.

Xenon Pharmaceuticals has a net margin of -163.05% compared to Canopy Growth's net margin of --. Canopy Growth's return on equity of -87.32% beat Xenon Pharmaceuticals's return on equity of --.

Canopy Growth has a consensus price target of $2.23, signalling upside risk potential of 70.6%. On the other hand Xenon Pharmaceuticals has an analysts' consensus of $57.18 which suggests that it could grow by 63.27%. Given that Canopy Growth has higher upside potential than Xenon Pharmaceuticals, analysts believe Canopy Growth is more attractive than Xenon Pharmaceuticals.

Canopy Growth has a beta of 0.790, which suggesting that the stock is 21.029% less volatile than S&P 500. In comparison Xenon Pharmaceuticals has a beta of 1.212, suggesting its more volatile than the S&P 500 by 21.174%.

Canopy Growth has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xenon Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Canopy Growth pays -- of its earnings as a dividend. Xenon Pharmaceuticals pays out -- of its earnings as a dividend.

Canopy Growth quarterly revenues are $53.3M, which are larger than Xenon Pharmaceuticals quarterly revenues of --. Canopy Growth's net income of -$86.8M is lower than Xenon Pharmaceuticals's net income of -$65.7M. Notably, Canopy Growth's price-to-earnings ratio is -- while Xenon Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Canopy Growth is 0.59x versus 207.11x for Xenon Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.